Literature DB >> 20169578

Influence of a low dose of amphetamine on vesicular monoamine transporter binding: a PET (+)[11C]DTBZ study in humans.

Isabelle Boileau1, Sylvain Houle, Pablo M Rusjan, Yoshiaki Furukawa, Diana Wilkins, Junchao Tong, Peter Selby, Alan A Wilson, Stephen J Kish.   

Abstract

We previously reported increased binding of (+)[11C]DTBZ (dihydrotetrabenazine), the vesicular monoamine transporter (VMAT2) positron emission tomography (PET) radioligand, in striatum of some methamphetamine users. This finding might be explained by stimulant-induced vesicular DA depletion resulting in decreased DA (+)[11C]DTBZ competition at VMAT2. In a prospective PET study, we now find that administration of an acute oral dose of amphetamine (0.4 mg/kg) to humans does not cause increased striatal (+)[11C]DTBZ binding but a slight 5% decrease. Our data suggest that a low amphetamine dose is unlikely to cause sufficient DA depletion to detect increased (+)[11C]DTBZ binding and that a higher dose might be required.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20169578     DOI: 10.1002/syn.20743

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  8 in total

Review 1.  VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse.

Authors:  Lee E Eiden; Eberhard Weihe
Journal:  Ann N Y Acad Sci       Date:  2011-01       Impact factor: 5.691

Review 2.  Brain dopaminergic system changes in drug addiction: a review of positron emission tomography findings.

Authors:  Haifeng Hou; Chunyan Wang; Shaowei Jia; Shu Hu; Mei Tian
Journal:  Neurosci Bull       Date:  2014-09-28       Impact factor: 5.203

3.  In vivo evidence for low striatal vesicular monoamine transporter 2 (VMAT2) availability in cocaine abusers.

Authors:  Rajesh Narendran; Brian J Lopresti; Diana Martinez; Neale Scott Mason; Michael Himes; Maureen A May; Dennis C Daley; Julie C Price; Chester A Mathis; W Gordon Frankle
Journal:  Am J Psychiatry       Date:  2011-10-31       Impact factor: 18.112

4.  Distribution of vesicular monoamine transporter 2 protein in human brain: implications for brain imaging studies.

Authors:  Junchao Tong; Isabelle Boileau; Yoshiaki Furukawa; Li-Jan Chang; Alan A Wilson; Sylvain Houle; Stephen J Kish
Journal:  J Cereb Blood Flow Metab       Date:  2011-04-27       Impact factor: 6.200

5.  Effect of STN DBS on vesicular monoamine transporter 2 and glucose metabolism in Parkinson's disease.

Authors:  Gwenn S Smith; Kelly A Mills; Greg M Pontone; W Stanley Anderson; Kate M Perepezko; James Brasic; Yun Zhou; Jason Brandt; Christopher R Butson; Daniel P Holt; William B Mathews; Robert F Dannals; Dean F Wong; Zoltan Mari
Journal:  Parkinsonism Relat Disord       Date:  2019-04-16       Impact factor: 4.891

6.  Rapid Recovery of Vesicular Dopamine Levels in Methamphetamine Users in Early Abstinence.

Authors:  Isabelle Boileau; Tina McCluskey; Junchao Tong; Yoshiaki Furukawa; Sylvain Houle; Stephen J Kish
Journal:  Neuropsychopharmacology       Date:  2015-08-31       Impact factor: 7.853

7.  Functional and structural brain changes associated with methamphetamine abuse.

Authors:  Reem K Jan; Rob R Kydd; Bruce R Russell
Journal:  Brain Sci       Date:  2012-10-01

8.  A Novel Potential Positron Emission Tomography Imaging Agent for Vesicular Monoamine Transporter Type 2.

Authors:  Zih-Rou Huang; Chia-Ling Tsai; Ya-Yao Huang; Chyng-Yann Shiue; Kai-Yuan Tzen; Ruoh-Fang Yen; Ling-Wei Hsin
Journal:  PLoS One       Date:  2016-09-09       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.